• PDS Biotech to Participate in Cantor’s Future of Oncology Virtual Symposium 

    المصدر: Nasdaq GlobeNewswire / 29 مارس 2023 07:30:00   America/New_York

    FLORHAM PARK, N.J., March 29, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, today announced that Dr. Frank Bedu-Addo, President and Chief Executive Officer, will participate in Cantor’s Future of Oncology Virtual Symposium being held on April 3-5, 2023.

    Cantor Symposium
    Presentation Date: Tuesday, April 4, 2023
    Time: 3:00 PM ET

    For more information about the conference, please contact your Cantor representative directly.

    About PDS Biotechnology
    PDS Biotech is a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer and infectious disease immunotherapies based on our proprietary Versamune®, Versamune® plus PDS0301, and Infectimune™ T cell-activating platforms. We believe our targeted immunotherapies have the potential to overcome the limitations of current immunotherapy approaches through the activation of the right type, quantity and potency of T cells. To date, our lead clinical candidate, PDS0101, has demonstrated the ability to reduce tumors and stabilize disease in combination with approved and investigational therapeutics in patients with a broad range of HPV16-associated cancers. Our Infectimune™ based vaccines have also demonstrated the potential to induce not only robust and durable neutralizing antibody responses, but also powerful T cell responses, including long-lasting memory T cell responses in pre-clinical studies to date. To learn more, please visit www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.

    Investor Contacts:
    Deanne Randolph
    PDS Biotech
    Phone: +1 (908) 517-3613
    Email: drandolph@pdsbiotech.com 

    Rich Cockrell
    CG Capital
    Phone: +1 (404) 736-3838
    Email: pdsb@cg.capital

    Media Contacts:
    Tiberend Strategic Advisors, Inc.
    Dave Schemelia
    Phone: +1 (609) 468-9325
    dschemelia@tiberend.com

    Bill Borden
    Phone: +1 (732) 910-1620
    bborden@tiberend.com


    Primary Logo

شارك على،